All Fred Grossman (President and Chief Medical Officer at Coya Therapeutics) articles
-
ArticleIL-2 and GLP-1 receptor agonist combination tackles neuroinflammation
Can targeting both regulatory and inflammatory pathways change how we treat neurodegenerative disease? Coya Therapeutics is testing that idea with its IL-2 and GLP-1 receptor agonist combination.